Published: Thu, February 08, 2018
Economy | By

Gilead Sciences Tops Fourth-Quarter Sales, Earnings Views

Gilead Sciences Tops Fourth-Quarter Sales, Earnings Views

FMR LLC grew its stake in shares of Gilead Sciences by 1.1% during the second quarter.

GILD stock fell 0.5% after the bell Tuesday afternoon. At one point in the past year, the shares traded as low as $13.80 but has recovered 26.59% since then. T. Rowe Price Group, Inc. (NASDAQ:EHTH) has risen 26.30% since February 7, 2017 and is uptrending. It has underperformed by 20.92% the S&P500. (GILD) has a market cap of $107.23 billion and over the last 12 months, Gilead Sciences, Inc. Paloma Partners Management Company sold 248,700 shares as the company's stock declined 8.05% while stock markets rallied.

Quarterly sales of hepatitis C drugs totaled $1.5 billion, down from $3.2 billion a year earlier, but in line with analysts' forecasts.

-Earnings (Q4): $2.34 Bln. vs. $3.59 Bln. a year ago. There were 117 sold out positions, on the other hand, totaling 11,852,687 shares. (NASDAQ:GILD). Quantres Asset Management holds 0.7% of its portfolio in Gilead Sciences, Inc.

Among 2 analysts covering Twenty-First Century Fox (NASDAQ:FOX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 64% are positive. The firm had revenue of $5.95 billion during the quarter, compared to analysts' expectations of $5.71 billion. The firm has "Buy" rating by Maxim Group given on Thursday, November 30. The stock of Merck & Co., Inc. Argus Research upgraded it to "Buy" rating and $72 target in Friday, February 5 report. The stock has "Outperform" rating by RBC Capital Markets on Wednesday, July 29. As per Monday, January 8, the company rating was upgraded by Bank of America. On Friday, August 25 the stock rating was maintained by Morgan Stanley with "Underweight". "(GILD)" was first published by Registrar Journal and is the property of of Registrar Journal. (NASDAQ:TROW) rating on Tuesday, October 10. There are brokerage firms with lower targets than the average, including one setting a price target of $130. Jefferies has "Hold" rating and $97 target. Jefferies maintained eHealth, Inc.

The collective rating of 2.2 for Gilead Sciences, Inc. $839,833 worth of stock was sold by MORELAND KENNETH V on Tuesday, January 2. The insider NELSON RONALD L sold $10.26 million. Insiders have sold 414,999 shares of company stock valued at $32,335,540 over the last 90 days. $84,292 worth of T. Rowe Price Group, Inc. (NASDAQ:CAR) on Thursday, August 31. (NASDAQ:TROW) on Thursday, December 14. Its down 0.46, from 1.04 in 2017Q2. These holdings make up 76.46% of the company's outstanding shares. The day started at a price of $17.14 but then traded as high as $17.54 before giving part of the gains back.

Schwab Charles Investment Management Inc increased Qts Rlty Tr Inc (NYSE:QTS) stake by 22,577 shares to 222,922 valued at $11.67M in 2017Q3. (NASDAQ:GILD) for 30,538 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt invested in 0.01% or 27,233 shares. The Gross Margin Score of Gilead Sciences, Inc. (NASDAQ:GILD) for 33,818 shares. Capital Counsel Ltd Liability Corp reported 0.51% stake. 8,000 are held by Barbara Oil.

Other hedge funds have also bought and sold shares of the company. Qcm Cayman Ltd has 0.56% invested in Avis Budget Group, Inc. (NASDAQ:GILD). Van Strum And Towne invested 2.78% of its portfolio in Gilead Sciences, Inc. Cadence Mgmt Limited Liability Corp has 0.02% invested in Pitney Bowes Inc.

Afam reported 0.67% of its portfolio in Gilead Sciences, Inc. Therefore 70% are positive. Credit Suisse downgraded Gilead Sciences, Inc. Northwest Invest Counselors Ltd Llc owns 0.03% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 38,157 shares. Wells Fargo maintained the stock with "Hold" rating in Monday, November 6 report. The company now has a consensus rating of "Buy" and a consensus target price of $85.58. The stock of Comcast Corporation (NASDAQ:CMCSA) earned "Outperform" rating by Macquarie Research on Monday, October 24. The firm has "Buy" rating given on Wednesday, June 1 by Gabelli. It increased, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. (NASDAQ:FOX) on Thursday, February 18 with "Buy" rating.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. (NASDAQ:GILD). Cambridge holds 0.21% or 6,894 shares. 34 funds opened positions while 73 raised stakes. Capital Guardian Trust Co.'s holdings in Gilead Sciences were worth $6,036,000 at the end of the most recent quarter. Barclays Plc invested in 0.23% or 5.91M shares. Carl Domino holds 1.3% or 13,124 shares in its portfolio. 118,818 were reported by Castleark Lc. Finally, Vetr raised shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating and set a $91.98 price target on the stock in a report on Friday, October 13th. Bnp Paribas Arbitrage Sa has invested 0.43% of its portfolio in Gilead Sciences, Inc. Qci Asset Management Incorporated accumulated 0.01% or 656 shares. State Of Alaska Department Of Revenue reported 0% stake. Recently attention has been given to shares of NIKE, Inc.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. Syntal Cap Ltd Limited Liability Company has 14,544 shares.

Like this: